71 West Capital Partners Has $3.16 Million Stock Holdings in AbbVie Inc. $ABBV

71 West Capital Partners raised its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 45.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,555 shares of the company's stock after acquiring an additional 3,901 shares during the quarter. 71 West Capital Partners' holdings in AbbVie were worth $3,159,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Norges Bank bought a new position in AbbVie during the 4th quarter worth $5,865,055,000. Wellington Management Group LLP increased its position in AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after acquiring an additional 8,646,424 shares during the period. Capital World Investors raised its stake in AbbVie by 106.3% in the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company's stock worth $2,986,777,000 after purchasing an additional 6,736,161 shares in the last quarter. Cardano Risk Management B.V. raised its stake in AbbVie by 914.6% in the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company's stock worth $1,244,112,000 after purchasing an additional 4,908,260 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in AbbVie by 10.4% in the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company's stock valued at $10,179,099,000 after purchasing an additional 4,190,487 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New lung-cancer data supports AbbVie’s long-term growth strategy. At the 2026 World Conference on Lung Cancer, AbbVie presented clinical, translational and real-world data for investigational programs including ABBV-1480, telisotuzumab adizutecan and ABBV-706 across non-small cell and small cell lung cancer. The updates highlight potential future oncology revenue sources beyond the company’s established immunology portfolio. AbbVie WCLC 2026 announcement
• Positive Sentiment: AbbVie is broadening its aesthetics pipeline. The company has initiated a Phase 2 study evaluating a treatment for forehead lines, adding another potential product to its aesthetics franchise and reinforcing efforts to diversify growth. AbbVie aesthetics pipeline update
• Neutral Sentiment: AbbVie’s relatively low market correlation reflects its defensive pharmaceutical revenue base. Investor performance is driven more by product demand, reimbursement and payer dynamics than by broad equity-market movements. This may help explain the stock’s resilience, but the article does not identify a new earnings catalyst. What Moves AbbVie Stock
• Neutral Sentiment: AbbVie recently reported quarterly EPS and revenue above consensus, with revenue rising 10.2% year over year, and guided to third-quarter EPS of $3.84–$3.88. Analysts’ average price target of $275.73 remains above the current trading level, although the stock’s elevated valuation raises expectations. AbbVie stock and earnings information
• Negative Sentiment: An early end to a long-term emraclidine schizophrenia study introduces uncertainty. Investors may question the implications for AbbVie’s neuroscience pipeline and the program’s development prospects until the company provides additional details. AbbVie emraclidine study update
• Negative Sentiment: An executive vice president sold approximately $8.18 million of ABBV shares, reducing his position by about 30.5%. The sale may weigh modestly on sentiment, although insider transactions can reflect personal financial planning rather than a change in business outlook. AbbVie insider sale

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Canaccord Genuity Group raised their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Sanford C. Bernstein reissued a "market perform" rating on shares of AbbVie in a research report on Tuesday, June 23rd. Wall Street Zen lowered AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 5th. UBS Group lifted their price objective on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a report on Monday, July 13th. Finally, Bank of America upped their target price on AbbVie from $234.00 to $276.00 and gave the company a "buy" rating in a research report on Friday, July 10th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $275.95.

Insider Transactions at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by insiders.

AbbVie Stock Performance

AbbVie stock opened at $265.62 on Monday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47. The stock has a market capitalization of $469.29 billion, a P/E ratio of 75.03, a price-to-earnings-growth ratio of 0.88 and a beta of 0.30. The stock has a fifty day moving average of $248.48 and a 200-day moving average of $227.50.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business's quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts forecast that AbbVie Inc. will post 14.06 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's dividend payout ratio is presently 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source